Breaking News
February 19, 2018 - Psoriasis drug also effective at reducing aortic inflammation
February 19, 2018 - Excess emissions can make serious contributions to air pollution, study shows
February 19, 2018 - Diabetes Drugs Differ on HF; School-Based Obesity Program Flop; Plaque Type in ACS
February 19, 2018 - Surgical infections linked to drug-resistant bugs, study suggests
February 19, 2018 - Poor awareness may hinder a child’s early dental care
February 19, 2018 - FDA Approves Apalutamide (Erleada) to Help Curb a Tough-to-Treat Prostate Cancer
February 19, 2018 - Educational Tool Boosts Cervical Length Screening
February 19, 2018 - Spider’s web inspires removable implant that may control type 1 diabetes
February 19, 2018 - University Hospital of Santiago de Compostela participates in large pancreatic cancer study
February 19, 2018 - New blood test shows promise to revolutionize diagnosis of tick-borne diseases
February 19, 2018 - Report: Use, Not Price, Drives State Health Costs
February 19, 2018 - Emergency services crews often unprepared for diabetic crises
February 19, 2018 - Scientists in Sweden create DNA nanowires that offer hope for treatment of diseases
February 19, 2018 - ID Break: Clean Hands, Fewer Abx; $11 Million HIV Cure?; MenB Vax for Kids
February 19, 2018 - Patient exposure to X-rays depends on how dentists are paid
February 19, 2018 - Study reveals parents’ views toward children’s tanning bed use
February 19, 2018 - Shot may help reduce risk of shingles
February 19, 2018 - FDA approves first treatment to reduce risk of NSCLC progression
February 19, 2018 - FDA Expands Approval of Imfinzi (durvalumab) to Reduce the Risk of Non-Small Cell Lung Cancer Progressing
February 19, 2018 - D.C. Week: Congress Passes Spending Bill
February 19, 2018 - Heart-muscle patches made with human cells improve heart attack recovery
February 19, 2018 - FDA Approves First Blood Test to Detect Concussions
February 19, 2018 - Survival Bump in Bladder Cancer with Keytruda
February 18, 2018 - Scientists describe the mechanism of heart regeneration in the zebrafish
February 18, 2018 - Scientists uncover the structure of microtubule motor proteins
February 18, 2018 - Light-activated cancer drugs without toxic side effects are closer to becoming reality
February 18, 2018 - Pioneering research could provide novel insight into how genomic information is read
February 18, 2018 - Pearls From: David Putrino, PhD
February 18, 2018 - Researchers uncover how cancer stem cells drive triple-negative breast cancer
February 18, 2018 - Morning Break: Anti-Anti-Vaxxers; Private Piercings Prohibited; A Case for Pelvic Massage
February 18, 2018 - Lower-dose radiation effective, safe for HPV+ head and neck cancer after induction chemo
February 18, 2018 - Specialist residential service for adults with autism opens in Swansea
February 18, 2018 - FDA Moves to Limit Loperamide Doses per Package
February 18, 2018 - Alcohol use disorder – Genetics Home Reference
February 18, 2018 - Autism might be better detected using new two-minute questionnaire
February 18, 2018 - Hand hygiene-intervention practices may reduce risk of infection among nursing home patients
February 18, 2018 - Researchers develop most sophisticated mini-livers to date
February 18, 2018 - Obamacare Helped More Young Women Get Prenatal Care: Study
February 18, 2018 - School-Based Program Fails to Dent Kids’ Obesity
February 18, 2018 - Research compares neural activity in children with and without autism spectrum disorder
February 18, 2018 - Poor fitness levels increase the risk dementia, concludes study
February 18, 2018 - Risk Score May Reveal if Kids are Victims of Ill-Treatment
February 18, 2018 - Adding Folic Acid to Corn Masa Flour May Prevent Birth Defects
February 18, 2018 - Acute treatment suppresses posttraumatic arthritis in ankle injury
February 18, 2018 - A Role for Budesonide in Autoimmune Hepatitis?
February 18, 2018 - Lupus patients exhibit altered cell proteins, a discovery with potential implications for diagnostics
February 18, 2018 - Muscle plays vital role in regulating heat loss from the hands
February 18, 2018 - High-tech brain scans can provide new way to define intelligence
February 18, 2018 - Study reveals the association between ultra-processed foods and cancer
February 18, 2018 - Prescription Opioid Use Tied to Higher Pneumonia Risk
February 18, 2018 - A non-invasive method to detect Alzheimer’s disease
February 18, 2018 - Deletion of specific enzyme leads to improvement in memory and cognitive functions
February 18, 2018 - Amyloid protein may be transmitted through neurosurgical instruments, study suggests
February 18, 2018 - Electric brain signals of males and females show differences
February 18, 2018 - American Heart Association commends McDonald’s for offering healthier menu in kids’ meals
February 18, 2018 - Parents Find Kids’ Weight Report Cards Hard to Swallow
February 18, 2018 - Does a Financial Conflict of Interest Ever Expire?
February 18, 2018 - Exercise can improve Alzheimer’s symptoms
February 18, 2018 - Scientists develop green chemistry method to improve pharmaceutical manufacturing efficiency
February 17, 2018 - ‘A Time Clock to a Tissue Clock’ for Acute Stroke Care
February 17, 2018 - Cancer Care Gets Personal | NIH News in Health
February 17, 2018 - Do more youth use or do youth use more?
February 17, 2018 - Eating faster linked to obesity
February 17, 2018 - Who’s Still Smoking? ACS Report Highlights Most Vulnerable Adults
February 17, 2018 - Study of smoking and genetics illuminates complexities of blood pressure
February 17, 2018 - Study reveals new link between bone cells and blood glucose level
February 17, 2018 - Children with reading challenges may have lower than expected binocular vision test results
February 17, 2018 - Mass Shootings Trigger Change for Emergency Medicine
February 17, 2018 - ECMO helps revive woman thought to be drowned
February 17, 2018 - Learning stress-reducing techniques may benefit people with epilepsy
February 17, 2018 - Shedding Pounds Before Weight-Loss Surgery a Smart Move
February 17, 2018 - FDA Approves New Cystic Fibrosis Drug Combo
February 17, 2018 - Augmented Reality helps surgeons to ‘see through’ tissue and reconnect blood vessels
February 17, 2018 - Emotional state affects operation of the entire brain instead of being restricted to specific regions
February 17, 2018 - Apalutamide Slows Metastasis in Prostate Cancer
February 17, 2018 - Kids’ well visits linked to lower appendicitis complications
February 17, 2018 - New NK cell-based immunotherapy effective against several types of leukemia
February 17, 2018 - Producing Super-Swelled Lyotropic Crystals for Drug Development
February 17, 2018 - Pfizer Receives Breakthrough Therapy Designation from FDA for PF-04965842, an oral JAK1 Inhibitor, for the Treatment of Patients with Moderate-to-Severe Atopic Dermatitis
February 17, 2018 - Molecular Imaging Flags Risk of AAA Rupture
Xtandi Shows Potency in Advanced AR-Positive TNBC Breast Cancer

Xtandi Shows Potency in Advanced AR-Positive TNBC Breast Cancer

image_pdfDownload PDFimage_print

Action Points

  • Androgen blockade with enzalutamide (Xtandi) in advanced triple-negative breast cancer (TNBC) expressing the androgen receptor (AR) has demonstrated positive clinical activity, in a prospective phase II trial.
  • Note that TNBC is a heterogeneous subgroup of breast cancer defined by a lack of expression of targetable receptors and carries the worst prognosis among all breast cancer subtypes.

The largest prospective trial to date of androgen blockade in advanced triple-negative breast cancer (TNBC) has demonstrated positive clinical activity using the prostate cancer drug enzalutamide (Xtandi, Medivation/Astellas Pharma) to target tumors expressing the androgen receptor (AR).

Published online in the Journal of Clinical Oncology, the phase II analysis met its primary endpoint, showing a clinical benefit rate (CBR) of 25% at 16 weeks in the overall intent-to-treat (ITT) group (95% CI 17%-33%) and 33% in a subgroup (95% CI 23%-45%).

Attempts to use targeted therapy to treat this poor-prognosis breast cancer subtype, described in 2005, have experienced little success, showing modest or no improvements in progression-free and overall survival (PFS, OS), noted the investigators, led by Tiffany Traina, MD, of Memorial Sloan Kettering Cancer Center in New York City. Mounting research suggests that this AR antagonist, used in castration-resistant prostate cancer, may be the answer to an unmet treatment need in a subgroup of TNBC, which has the worst outcome of all three major breast cancer types. Interest has been growing in this targeted approach, as MedPage Today reported last year.

“Data from this phase II study in a group of patients with AR-positive TNBC support and build upon the findings from others that there seems to exist a subset of patients with androgen-driven TNBC who may benefit from an AR-targeted agent,” Traina and co-authors wrote.

With tumor sample collection begun in 2013, the 2-year study originally enrolled 118 patients with locally advanced or metastatic TNBC from 45 sites in seven countries. The mean age of patients was 57 years, and 77% were white. TNBC was defined as <1% staining for estrogen and progesterone receptor and for human epidermal growth factor receptor 2, 0, or 1+ by immunochemistry (IHC) staining or negative by in situ hybridization.

An IHC assay, optimized with two AR antibodies for breast rather than prostate cancer, tested tumor samples, with any nuclear AR staining greater than 0% considered positive. A subgroup consisting of patients with tumors expressing at least 10% nuclear AR was also identified. Nearly 80% of samples expressed nuclear AR of of more than 0%, while 5 5% had AR of 10% or more. All patients received enzalutamide 160 mg once daily until disease progression, with a median duration of treatment of 8.1 weeks.

In secondary study endpoints, median PFS was 2.9 months (95% CI 1.9-months) in the ITT population and 3.3 months (95% CI 1.9-4.1 months) in the evaluable subgroup. Median OS at 18 months’ follow-up was 12.7 months (95% CI 8.5 to 16.5) in the ITT population and 16.5 months (95% CI 12.7-20) in the evaluable >10% subgroup. Complete or partial response was observed in 8% of subgroup and 6% of ITT patients.

“Treatment targeting AR has been studied in TNBC now for several years, so it is not completely novel, Hope S. Rugo, MD, of University of California San Francisco Hellen Diller Family Comprehensive Cancer Center (and not involved in the study), told MedPage Today. “What is novel is this drug itself, which appears to be a more potent antagonist of AR.”

In terms of safety, enzalutamide was well tolerated, with adverse events well within the drug’s known profile. Eight patients stopped treatment because of some adverse event. The only treatment-related grade 3 or higher adverse event occurring in more than 2% was fatigue.

Last year, a phase I/Ib study by Traina’s group reported positively on the safety of enzalutamide alone or combined with endocrine therapies in advanced breast cancer. And, in the past few years, positive antitumor activity with AR inhibition has also been reported in two prospective phase II AR-positive breast cancer trials of two other antagonists, bicalutamide (Casodex) with a 6-month CBR of 19%, and abiraterone acetate (Zytiga) combined with prednisone, with a 6-month CBR of 20%.

Compared with bicalutamide, the authors pointed out, enzalutamide has no known AR agonist activity and has proven superior to bicalutamide in phase II prostate cancer studies. As for abiraterone acetate, it requires concomitant prednisone, which stimulates the glucocorticoid receptor, expressed in approximately 25% of TNBCs and possibly stimulative of tumor growth. The drug also increases progesterone, potentially stimulating the progesterone receptor even at the low levels seen in TNBC.

According to the authors, their findings support the need for “novel, well-tolerated therapies administered in earlier treatment settings.”

Added Rugo, “AR blockade is overall well tolerated, and it is likely that response will be better if it is used earlier, before additional mechanisms of resistance develop.” Another advantage of earlier treatment is that patients may be able to start with oral medication. “Quality of life is better than with chemotherapy, so a trial in an appropriate patient early in the course of metastatic disease seems reasonable,” Rugo said.

In the meantime, oncologists are awaiting data on a potential gene signature to identify precisely the patients most likely to benefit from AR inhibition. “Overall we expect that, at most, 10% of patients with TNBC both have AR positive-disease and are candidates for a treatment like enzalutamide, and of those about 25% appear to benefit,” said Rugo. “We don’t as yet have a reliable and definitive test for AR expression that correlates with response, but work is ongoing to identify gene signatures that may be a better marker of responsiveness. If these data become available, we will be better placed to study enzalutamide either as a single agent compared with standard therapy or in rationale combinations.”

In Rugo’s view, the data from Traina and colleagues suggest that enzalutamide may be the most active agent to date in this setting. “Regardless, AR antagonists are potential therapy for a very small number of patients with AR-positive TNBC, she said. She noted that newer AR antagonists are under study and that larger, more definitive studies are expected to shed further light in this area of treatment.

As a possible study limitation, the authors cited the suboptimal performance of IHC as a treatment-guiding and potentially predictive assay. In 2017, Kumar et al reported a threshold of >10% nuclear expression had a positive predictive value of AR of only 30%, which may restrict clinical application. “This is a critical consideration in the development of a treatment-associated assay, because one would not want to exclude patients from receiving a potentially beneficial and well-tolerated treatment,” Traina and associates wrote.

Supported in part through National Institutes of Health/National Cancer Institute Cancer Center and by Medivation, a Pfizer company, and Astellas Pharma, co-developers of enzalutamide.

Lead author Traina disclosed ties to Genentech, Eisai, Mundipharma, Pfizer, AstraZeneca, Bayer, Immunomedics, Merck, Medivation, Celgene, Innocrin Pharma, Genomic Health Research Funding, Astellas Pharma, Eisai, Pfizer, Novartis, Innocrin Pharma, and AstraZeneca.


Tagged with:

About author

Related Articles